Effects of estroprogestins containing natural estrogen on vaginal flora
article
OA: closed
CC0
⤵ 4 in-corpus citations
Abstract
Estroprogestins with "natural oestrogen" has represented a new option in terms of combined hormonal contraception. So, the aim of this study is to investigate how estroprogestins with natural estrogen may modify the vaginal niche. In literature, very few studies focused on the interaction between hormonal contraception and vaginal milieu. This is a prospective comparative study. We enrolled 60 women from January 2013 to September 2013, 30 of them were administered estradiol valerate dienogest (E2V+DNG - Klaira®) in a quadriphasic regimen, while the other 30 women were administered 17-β estradiol with nomestrol acetate (EV+NOMAC - Zoely®) in a monophasic regimen. After a baseline study of vaginal milieu at recruitment of patients (Gram stain with Nugent score, vaginal pH, vaginal wet mount for the quantification of leukocytes, Lactobacilli and/or presence of Candida), we performed the same follow-up after six months of estroprogestin therapy. Our results showed that the women treated with E2V+DNG had a trend of an improvement of vaginal health in terms of increase of lactobacillar flora and reduction of vaginal pH in place of women treated with EV+NOMAC that showed a reduction of cervical mucus. Finally, our data about the effects on vaginal flora exerted by two estroprogestin pills (EPs) containing a natural estrogen suggest slight, but interesting differences in terms of vaginal ecology. These differences could be related to the type of estrogen, type of progestin, regimen of administration and, after all, to the net balance between estrogenic and progestin component of the EPs.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (4)
- Needs, expectations and doubt users of hormonal contraceptives 2020
- Satisfaction of young women with estradiol valerate/dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN 2025
- Real clinical practice and contraception for young women with children 2021
- Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest 2019
References (15)
- Estradiol valerate and dienogest: a new approach to oral contraception via openalex
- doi:10.1016/j.contraception.2010.08.007 via openalex
- doi:10.1186/1471-2490-12-22 via openalex
- doi:10.1097/olq.0b013e31811ed0e4 via openalex
- doi:10.1086/503780 via openalex
- doi:10.1067/mob.2001.115862 via openalex
- doi:10.1016/j.contraception.2012.02.012 via openalex
- doi:10.1016/j.contraception.2009.12.011 via openalex
- doi:10.1016/j.contraception.2009.01.008 via openalex
- doi:10.1210/en.2004-1153 via openalex
- doi:10.1016/j.steroids.2011.02.002 via openalex
- doi:10.1016/j.jpag.2006.11.009 via openalex
- doi:10.1016/s0010-7824(00)00155-4 via openalex
- doi:10.1258/095646207780749583 via openalex
- doi:10.1016/j.contraception.2007.09.009 via openalex
Cited by (4)
- Satisfaction of young women with estradiol valerate/dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN 2025
- Real clinical practice and contraception for young women with children 2021
- Needs, expectations and doubt users of hormonal contraceptives 2020
- Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest 2019
Source provenance
- openalex
- last seen: 2026-05-11T06:35:44.859312+00:00
License: CC0
· commercial use OK